anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A viscosity building composition is described. The viscosity building composition comprises a fatty alcohol in combination with one or more polyglyceryl esters. In one embodiment, the composition contains a fatty alcohol in combination with a polyglyceryl monoester. In an alternative embodiment, the composition contains a fatty alcohol combined with a polyglyceryl polyester, such as a polyglyceryl diester or a polyglyceryl triester. In still another embodiment, the composition comprises a fatty alcohol mixed with a blend of polyglyceryl esters. The blend may include at least one polyglyceryl monoester in combination with at least one polyglyceryl polyester, such as a diester, triester, tetraester or decaester. The polyglyceryl polyester is present generally in an amount greater than the monoester. In an alternative embodiment, the blend may include two or more polyglyceryl polyesters. The blend of polyglyceryl esters has been found to dramatically enhance the ability of the fatty alcohol to increase viscosity and build body in personal care products.
Patients who are eligible (newly diagnosed hormone positive clinical stage 1 or 2 breast cancer) will be approached about the study. If they sign informed consent a prescription for 21 doses of Tamoxifen will be provided. The patient's surgery will be scheduled at a time convenient for the patient and the surgeon. Once the surgery has been scheduled, a medication calendar will be completed that allows the patient to take tamoxifen for 7 days preoperatively with the 7th dose of tamoxifen to coincide with the day before surgery. The patient will continue to take tamoxifen for 2 weeks (14 days) after surgery. Patients will then proceed along normal treatment guidelines. For those needing chemotherapy or radiation therapy, we recommend the long term endocrine therapy start at the conclusion of chemo and/or radiation treatments. For those not going on to any additional therapy, the prescription for endocrine therapy will be written at the initial post-operative visit.

Unstained slides from the formalin-fixed, paraffin-embedded tissue blocks from the patient's breast tissue from which the original diagnosis of breast cancer was made by H\&E will be stained for Ki67. After endocrine therapy and subsequent resection, carcinoma will be confirmed by the participating pathologist on H\&E, and Ki67 will be performed on unstained slides from a representative tissue block containing invasive carcinoma. The pathologist will circle a designated area of tumor on the H\&E slide and both the H\&E and immunostained (Ki67) slides will be scanned in a digital imaging device (Aperio XT Scanscope), which quantitatively analyzes the tumor designated by the pathologist with image analysis algorithms. The algorithm accurately detects regions of interest and distinguishes cells and sub-cellular objects within these target regions. It determines morphology and expression profiles per individual cell or cell compartment. For Ki67 analysis, a nuclear Immunohistochemistry (IHC) algorithm will be used.
Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
PURPOSE:To obtain the subject agent capable of sustainably and topically suppressing the sebum secretion on the skin or scalp, and also having no side effect and good in safety. CONSTITUTION:This sebum secretion suppressive agent contains, as active ingredient, at least one kind of compound selected from 6-20C carboxylic acids of the formula ((n) is an integer of >=1; Y is a <=8C mono or dihydroxy- substituted straight chain or branched alkyl), salts thereof, ester derivative therefrom and amide derivative therefrom. In the above formula, it is preferable that Y is a straight chain alkyl with OH group substituted within the range from the terminal (omega-site) to omega-6 site and (n) 7-10. The salt is pref. ammonium, an alkanolamine or amino acid salt; and the ester derivative is ref. an alkyl ester, branched alkyl ester, aryl ester or polyhydric alcohol ester. It is preferable that the amount of this compound to be formulated is 0.1-10wt.% based on the whole amount of a cosmetic to be used.
Chemotherapy and other cancer treatments can cause damage to the peripheral nerves mainly reflected in severe pain in the upper and/or lower extremities. Additional to pain, cancer treatment may cause loss of balance which affects motor capacity and is a major cause of poor quality of life. There are only minimally effective treatments for CIPN despite over 20 years of research. Few recent studies have suggested that exercise intervention could be effective to restore numbness and motor capacity loss because of CIPN. Unfortunately, conventional rehabilitation programs however suffer from poor adherence and those programs for supervised settings have limitation of access for those who live in the remote areas (e.g., rural area), or could be too frail to travel after chemotherapy. This raised a significant disparity for delivering an effective therapy for those who are living in remote areas or those who are too frail to travel. Therefore, will test Quell® Transcutaneous Electrical Nerve Stimulation device developed by Neurometrix Inc. (Woburn, MA, USA), to mitigate the associated symptoms caused by CIPN. This device utilizes a wireless technology manageable through a smart phone application (Quell App) that also tracks symptom-status.

The investigators institution, Duncan Cancer Center (McNair Campus, Baylor College of Medicine St Luke's, Houston, Texas, USA) supervised by specialists in clinical and surgical oncology, has a high volume of patients that present with CIPN. Therefore, the investigators believe that this institution is a suitable place to perform this sub-study. The premise of this sub-study is that daily basis of TENS therapy could be effective to reduce pain, reduce numbness and improve both motor-capacity and mobility performance leading to improve quality of life in those who suffer from CIPN and have limited access to health care.
Women in this study arm receive 10 µg of vitamin D3 per day, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
FIELD: medicine, anesthesiology, resuscitation, surgery. SUBSTANCE: method deals with treating patients suffering diseases accompanied by severe endotoxicosis. One should carry out discrete eplasmapheresis by separating plasma against erythrocytic mass and substituting the volume of removed plasma with donor's one, moreover, before returning into patient's body erythrocytic mass should be treated with ozonized isotonic solution of sodium chloride at 200 ml volume and ozone concentration in solution being 2 mg/l. The present innovation enables to decrease toxicity of plasma and erythrocytes that leads to complete interruption of endotoxicosis. EFFECT: higher efficiency of therapy. 1 cl, 3 ex, 2 tbl
OBJECTIVE: To investigate the effects of chronic intermittent hypoxia (CIH) and reoxygenation on insulin resistance (IR) and expressions of miR-27a-3p/PPARγ/IRS1/PI3K/AKT in rat skeletal muscle.
METHODS: GEO database was used for screening the differentially expressed miRNAs in CIH, and their target genes were subjected to GO and KEGG enrichment analysis followed by construction of the miRNA-mRNA-pathway regulatory network using Cytoscape. In the animal experiment, 48 male SD rats were randomly divided into normoxia group and CIH group (8 weeks of CIH followed by 4 weeks of normoxic recovery). Blood and skeletal muscle samples were collected at baseline, 8 weeks, and 12 weeks to evaluate the changes in fasting blood glucose (FBG) and fasting insulin (FINS) levels and muscular pathology. RT-qPCR and Western blotting were used to detect the changes in the expressions of miR-27a-3p, PPARγ, GLUT4, IRS1, p-IRS1, PI3K, p-AKT and AKT in the muscular tissues.
RESULTS: No muscular miRNA datasets for CIH were available in GEO database, from which only a kidney-related dataset (GSE202480) was obtained, based on which a total of 165 differentially expressed miRNAs were identified. GO/KEGG analysis suggested that these miRNAs were involved in muscular regulation and insulin signaling. The miRNA-mRNA-pathway network highlighted miR-27a-3p as a crucial regulator in the PPAR and PI3K/AKT pathway. In the animal experiment, the rats subjected to CIH for 8 weeks showed significantly increased FBG, FINS, HOMA-IR, and PPARγ levels, loose muscle fiber arrangement, decreased cross-sectional area of the muscle fibers, and lowered expressions of miR-27a-3p, p-IRS1/IRS1, PI3K, and p-AKT/AKT in the skeletal muscles.
CONCLUSION: CIH increases IR, causes skeletal muscle pathology, downregulates miR-27a-3p expression, upregulates PPARγ expression, and inhibits IRS1/PI3K/AKT insulin signaling in the skeletal muscles of rats, and these changes can be reversed by reoxygenation. MiR-27a-3p may participate in CIH-induced IR by modulating the PPAR γ/IRS1/PI3K/AKT signaling pathway.
Women are provided antenatal care services on a first come, first serve basis and listen to a health lecture. They meet individually with a midwife for a physical assessment. Women complete laboratory tests (including HIV testing) at their first visit. Congruent with the new WHO recommendations, individual antenatal care consists of 8 antenatal care visits and 2 postnatal visits at 1 week and 6 weeks.
Patients in the portal anesthesia group will also receive 20 cc of 0.25% bupivacaine with epinephrine distributed evenly between portal sites. After completion of knee arthroscopy, portal tracts are closed and the knee is ensured to be evacuated of residual fluid. An 18G or 21G long needle is then used to infiltrate each portal tract where the anesthetic will be delivered.
A method for treating Aconiti tuber  comprises  (a)  leaching Aconiti tuber powder in distilled water for 10-20  hrs.,  and  (b) treating it with microwave for 5-15 mins. Pref. the wavelength  of the microwave is about 2450 MHz. The toxicity of Aconiti tuber  is reduced  by  deacetylation,  debenzoylation   and   oxidation   of aconitine alkaloids in the method. Aconiti tuber is  useful  as  a cardiotonic, a diuretic or an  analgesic;  and  has  highly  toxic alkaloids i.e. higenamine, aconitine, mesaconitine,  hypaconitine, etc.
No data are available regarding overdose of ACCRUFER in patients. Acute iron ingestion of 20 mg/kg elemental iron is potentially toxic and 200- 250 mg/kg is potentially fatal. Early signs and symptoms of iron overdose may include nausea, vomiting, abdominal pain and diarrhea. In more serious cases there may be evidence of hypoperfusion, metabolic acidosis and systemic toxicity.

Dosages of ACCRUFER in excess of iron needs may lead to accumulation of iron in storage sites leading to hemosiderosis. Periodic monitoring of iron parameters such as serum ferritin and transferrin saturation may assist in recognizing iron accumulation. Do not administer ACCRUFER to patients with iron overload [see Contraindications ( 4) ].
BACKGROUND: Reverse oblique intertrochanteric fractures (ROFs) are unstable extracapsular hip fractures that present a mechanical challenge. These fractures are classified as AO/Orthopaedic Trauma Association (OTA) 31-A3 according to the Trauma Association classification system and can further be subclassified into 3 subtypes based on their specific characteristics. The study aimed to evaluate and compare the radiographic and clinical outcomes of the 3 subtypes of ROFs.
METHODS: A retrospective study was conducted at a single high-volume, tertiary center, where data were collected from electronic medical records of consecutive patients who underwent surgical fixation of AO/OTA 31-A3 fractures. Patients with less than 1-year follow-up, pathological fractures, and revision surgery were excluded. The subtypes of fractures were classified as 31-A3.1 (simple oblique), 31-A3.2 (simple transverse), and 31-A3.3 (wedge or multi-fragmentary). The operation was done using 4 different fixation methods, and radiological evaluation was performed at routine intervals.
RESULTS: The final population consisted of 265 patients (60.8% women) with a mean age of 77.4 years (range, 50-100 years) and the mean follow-up time was 35 months (range, 12-116 months). The incidence of medical complications was similar across the groups. However, there was a trend toward a higher incidence of orthopedic complications and revision rates in the 31-A3.2 group, although this was not statistically significant (p = 0.21 and p = 0.14, respectively).
CONCLUSIONS: Based on the findings of this study, no significant differences were observed between the groups, indicating that the subclassifications of AO/OTA 31-A3 fractures do not have a significant impact on surgical outcomes or the occurrence of postoperative complications.
This is an open-label Phase 2 clinical study in patients with advanced colorectal cancer (CRC). Patients will be treated with 200mg/m2 of STA-9090 during a 1-hour intravenous infusion 1 time per week for three consecutive weeks followed by a 1 week dose-free interval. Patients tolerating STA-9090 will be permitted to continue treatment until disease progression.
RNA interference (RNAi) is a fundamental regulatory pathway with a wide range of functions, including regulation of gene expression and maintenance of genome stability. Although RNAi is widespread in the fungal kingdom, well-known species, such as the model yeast Saccharomyces cerevisiae, have lost the RNAi pathway. Until now evidence has been lacking for a fully functional RNAi pathway in Candida albicans, a human fungal pathogen considered critically important by the World Health Organization. Here, we demonstrated that the widely used C. albicans reference strain (SC5314) contains an inactivating missense mutation in the gene encoding for the central RNAi component Argonaute. In contrast, most other C. albicans isolates contain a canonical Argonaute protein predicted to be functional and RNAi-active. Indeed, using high-throughput small and long RNA sequencing combined with seamless CRISPR/Cas9-based gene editing, we demonstrate that an active C. albicans RNAi machinery represses expression of subtelomeric gene families. Thus, an intact and functional RNAi pathway exists in C. albicans, highlighting the importance of using multiple reference strains when studying this dangerous pathogen.
PROBLEM TO BE SOLVED: To obtain a UV sensor by which ultraviolet rays are confirmed easily and which can deal with a general demand, by a method wherein an adhesive layer and a sheet of exfoliation paper are pasted and formed on the rear of a film which reacts to the ultraviolet rays and this assembly is formed to be a required shape or the like. SOLUTION: A film 1 for UV check is formed in such a way that an adhesive layer 3 is formed on the rear of a reaction film 2 which reacts to ultraviolet rays, and that a sheet of exfoliation paper 4 is pasted on the layer. In this case, the film 2 is manufactured in such a way that a pigment (a photochromic color material) which displays a reaction action such as an alkyd-based compound or the like is kneaded and coated regarding the formation of a synthetic resin film such as a vinylchloride film or the like. Then, a rectangular card body is formed of a sheet of rigid paper or a thin sheet material made of a synthetic resin or a metal. Then, the film 1 is cut to be a glass shape, the sheet of exfoliation paper 4 is stripped, the film is bonded and fixed to the central part of the card body by using the adhesive layer 3, and a card for UV check is obtained.  In addition, the film 1 is cut to be shape of a horse's hoof, and a seal for UV check can be obtained.
Limited population-based data on the gender differences and association between arteriosclerotic calcification at different sites and atrial fibrillation (AF) exist. We aimed to investigate the (gender-specific) associations between arteriosclerotic calcification at different sites with the risk of AF in the general population. Arteriosclerotic calcification was quantified using computed tomography examinations between 2003 and 2006 in 2,259 participants free of AF from the population-based Rotterdam Study. Cox proportional hazards models, adjusted for cardiovascular risk factors, were used to assess the associations of volumes of coronary artery calcification (CAC), aortic arch calcification (AAC), extracranial and intracranial carotid arteries, vertebrobasilar arteries, and the aortic valve with incident AF. During a median follow-up of 8.6 years, 182 incident AF cases occurred. A larger CAC was associated with incident AF (hazard ratio [HR], 95% confidence interval [CI] 1.25 1.09 to 1.44, p = 0.0019). The gender-stratified analyses showed that larger CAC in men (HR 1.43, 95% CI 1.10 to 1.86, p = 0.0068) and larger AAC in women were associated with incident AF (HR1.44, 95% CI 1.04 to 2.01, p = 0.0299). In conclusion, CAC in the general population, especially in men, and AAC in women were significantly associated with new-onset AF. Our findings imply that interventions to lower arteriosclerotic calcification, particularly, CAC, carry potential for the prevention of AF in the general population, especially in men.
Female subjects were screened and randomized. Following two weeks of medication monitoring, all participants continued smoking as usual for one week, at which time baseline measurements were taken. For the remaining two weeks (the experimental period), participants were randomized to a continued smoking or smoking abstinence condition. The abstinent group was provided with cessation counseling and monitored for abstinence. For all participants, data were collected during five clinic visits on all dependent measures: MNWS, QSU, Beck Depression Inventory (BDI), Profile of Mood States, Motor Speed Tasks and Reaction Time Tests. Question of interest was whether hormone replacement therapy would improve these dependent measures as manifested during short-term smoking cessation.
Depression during pregnancy is prevalent (15-20%) and has an adverse impact on fetal outcomes including preterm delivery (PTD) and low birthweight (LBW). Currently, significant confusion exists about if and how depression during pregnancy should be treated, given the unknown risk-benefit profiles of various treatments. Kaiser Permanente Northern California has implemented a large scale universal peripartum depression screening program, annually screening more than 35,000 pregnant women. Taking advantage of this unique infrastructure, we propose to conduct a two-stage prospective cohort study to determine if treating depression in pregnancy is effective in improving fetal outcomes, and which treatment is most effective: pharmacotherapy, psychotherapy or a combination. The risk-benefit of the treatments will be examined separately for two depression types: pregnant women with depression only and those with other psychiatric comorbidities to evaluate possible differences in treatment effectiveness between the two groups. Stakeholders (patients, advocacy groups, and providers) are an integral part of the research team. Four cohorts with different treatment options including untreated will be formed within each depression type (with or without comorbidity): (A) "Antidepressant only": screen positive for depression and use only antidepressants during pregnancy; (B) "Psychotherapy only": screen positive and receive psychotherapy only; (C) "Combination therapy": screen positive and receive both antidepressants and psychotherapy; (D)"Untreated depression": screen positive and receive no treatment. A total of eight cohorts will be formed. A final cohort (E) "No depression": screen negative and receive no treatment, will be examined for baseline comparison. Information on depression treatment and PTD and LBW will be available for all participating women who will be followed until the end of pregnancy. Within each depression category, comparison of Cohort A, B \& C to D, respectively, will determine if treating depression is effective. Pair-wise comparisons among Cohorts A, B \& C will determine the comparative effectiveness of treatment regimens. Comparison of Cohort D to E provides baseline fetal risks of untreated depression. Findings will provide answers to long standing stakeholder questions of how to treat depression in pregnancy and which treatment is most effective with the best risk-benefit profile in improving fetal outcomes. Selecting an effective treatment could reduce PTD or LBW, thus, reducing infant mortality and morbidity, and medical costs.
UNLABELLED: The aim of this study was to investigate the effects of acupressure bladder meridian (ABM) on anxiety in rats with chronic stress.
METHODS: The sugar water preference (SPF), tail suspension time (TST) and forced swimming time (FST) of rats were measured. The levels of reactive oxygen species (ROS), myeloperoxidase (MPO) in hippocampus tissue, oxidative stress parameters and inflammatory cytokines were detected. Underlying mechanisms of ABM on anxiety were detected. lipopolysaccharide (LPS) stimulated PC12 cells were adopted in vitro. HMGB1 knockdown were used in PC12 cells, and related signaling was further detected.
RESULTS: ABM significantly increased SPF, decreased TST and FST. ABM decreased ROS, MPO levels, decreased the levels of inflammatory cytokines. Furthermore, ABM decreased the levels of oxidative stress index. ABM reduced the expression of inflammation-related proteins mediated by HMGB1, increased nuclear factor erythroid2-related factor 2 (Nrf-2) and hemeoxygenase-1 (HO-1). In vitro PC12 cells, Rat serum (RS-ABM) treated with ABM significantly decreased LPS induced inflammation-related proteins and increased Nrf-2/HO-1 pathway. HMGB1 knockdown inhibited LPS-induced PC12 cell inflammatory signaling pathway and increased Nrf-2/HO-1 pathway.
CONCLUSION: Our results demonstrated that ROS-dependent HMGB1 plays an important role in anxiety, and ABM exhibits inhibited inflammation in anxiety.
PURPOSE:To obtain the titled composition having high safety, by using a carbonate and an organic acid as essential components. CONSTITUTION:A remedy composition for Buerger disease is prepared by using a carbonate (e.g. NaHCO3, KHCO3, Na2CO3, etc.) and organic acid as essential components, at a ratio to give a pH of 4-7 as a 0.01wt% aqueous solution. For satisfying the above condition, the amount of the organic acid is preferably 20-200wt% of the carbonate, and in the case of using monosodium succinate, 40-400wt% of the carbonate. It is used by dissolving 5-250g of the remedy in 10-200 liters of water or hot water, and immersing the diseased part in the solution several times a day, for 10-30min each. The treatment is continued for several days - several months.